Febuxostat, effectve treatment for chronic gout and hyperuricemia

Published: 2004-11-04 06:57:00

Updated: 2004-11-04 06:57:00

SK Chemicals and SK Pharm said that TAP Pharmaceutical Products Inc., a joint venture between Abbott and Takeda Pharm, announced its October 19 data showing its investigational medication, febuxostat (codename: TMX-67), lowered uric acid levels among patients with chronic gout in a Phase II clini...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK